CUK is a stock that could be facing a big hit from the coronavirus in 2020

While investors have been anxious to find reasons to shrug off fears about the economic impact of coronavirus, there are certainly some individual cases where those risks can’t really be ignored. One in the Leisure & Recreation Services industry, which includes cruise line companies. News reports of cruise ships filled with passengers that have been turned away from multiple ports throughout the Asia-Pacific region, along with analyst estimates that have U.S. cruise sales down in the low double-digits, and increasing cancellations are all factors that could weigh on the industry throughout the year.

One of the most recognizable names in the cruise line segment is Carnival plc (CUK), whose brands include established names including Carnival, Princess Cruises, and Holland America. The company owns the the Westerdam, the ship that was turned away from four different ports despite the fact that there was no evidence that any of the 2,200+ people on board carried the virus. The company also told investors recently that they could face a per-share impact of 55 to 65 cents in earnings if operations are suspended in Asia through the end of April because of the outbreak. While that worst-case scenario appears unlikely, there will still be a material impact on the business that is yet to be fully realized. 

That certainty is a risk that has forced the stock, which appeared set to reverse its long-term downward trend at the end of 2019 to reverse back to approach its multiyear low near $36 per share. Its valuation metrics, not surprisingly, are compelling, which begs the question of whether CUK’s fundamentals support thinking about the stock as a long-term investment opportunity.

Fundamental and Value Profile

Carnival plc is a leisure travel company. The Company’s segments include North America, and Europe, Australia & Asia (EAA). Its North America segment includes Carnival Cruise Line, Princess Cruises (Princess), Holland America Line and Seabourn. Its EAA segment includes Costa Cruises (Costa), AIDA Cruises (AIDA), P&O Cruises (the United Kingdom), P&O Cruises (Australia) and Cunard. It also includes Cruise Support segment, which represents its portfolio of port destinations and private islands. In addition to its cruise operations, it owns Holland America Princess Alaska Tours, a tour company in Alaska and the Canadian Yukon. Its tour company owns and operates hotels, lodges, glass-domed railcars and motorcoaches. Its Carnival Cruise Line offers cruises generally from 3 to 8 days with almost all of its ships departing from 16 convenient United States home ports located along the East, Gulf and West coasts, Puerto Rico and Hawaii, as of November 30, 2016.CUK has a current market cap of about $11.6 billion.

Earnings and Sales Growth: Over the last twelve months, earnings decreased by about -11.5%, while revenues increased by about 7.25%. in the last quarter, earnings dropped a little more than -75% while sales slumped by almost -27%. The company’s margin profile is healthy, but narrowed in the last quarter, as Net Income as a percentage of Revenues in the last quarter was 8.82% versus 14.3% over the last twelve months.

Free Cash Flow: CUK’s free cash flow is minimal and declining significantly, at $72 million. That translates to a Free Cash Flow Yield of just .95%. It has also declined from more than $2.1 billion in November of 2018.

Debt to Equity: CUK’s debt to equity is .38, which signals a conservative approach to leverage that is a bit misleading by itself. The company’s balance sheet indicates cash and liquid assets are with $518 million versus $9.67 billion in long-term in the most recent quarter. While operating profits should be adequate to service their debt, their minimal Free Cash Flow and declining Net Income are sources of concern for the quarters ahead.

Dividend: CUK’s annual divided is $2.00 per share, which translates to a much larger-than-normal yield of about 4.9% at the stock’s current price.

Price/Book Ratio: there are a lot of ways to measure how much a stock should be worth; but one of the simplest methods that I like uses the stock’s Book Value, which for CUK is $36.01 and translates to a Price/Book ratio of 1.14. The stock’s historical average Price/Book ratio is 1.69, which puts the stock’s long-term target price at about $61 per share – almost 46% above the stock’s current price. The stock is also trading 57% below its historical Price/Cash Flow ratio, which offers a target price at nearly $66 per share.

Technical Profile

Here’s a look at the stock’s latest technical chart.

Current Price Action/Trends and Pivots: The chart above covers the last two years of price activity. The red line traces the stock’s downward trend to its low at around $38 per share in October of last year. It also informs the Fibonacci retracement lines shown on the right side of the chart. The stock rallied to a peak in late December a little above $48 per share before reversing and dropping quickly back to its current price below $42. Its most recent support is around $40; if the stock drops below that level the stock should test its two-year low at around $38 per share. A drop below that point could give the stock to keep dropping to between $35 and $36 per share – levels the stock hasn’t seen since the latter part of 2014. CUK would need to break above $43 to give the stock strong enough bullish momentum to keep rallying; in that case, it could push to somewhere between $45 and $48 per share.

Near-term Keys: Given the strength of the stock’s current bearish momentum, and the likelihood that even if the worst coronavirus fears aren’t realized, momentum is likely to continue to be strongly bearish. That means that the highest probability short-term trade would come from a push below $40, with room to drop to about $38 or possibly $35 if downward pressure increases. That would be a good signal to consider shorting the stock or working with put options. However, if the stock does find a stabilization point, and manages to push above $43, there could be a useful short-term opportunity to buy the stock or work with call options with an eye on $45 to $8 as a bullish target. The stock’s fundamentals are generally solid, and the value proposition is excellent, but given the current broader conditions and concerns, I think the stock is unlikely to see any kind of significant bullish momentum in the foreseeable future.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Natural Gas Utility Stocks To Buy Now

    Spire Inc. (SR) Spire Inc. is a natural gas utility company serving residential, commercial, and industrial customers. The company focuses on infrastructure modernization, energy efficiency, and expanding renewable natural gas... Read More

  • 3 Biopharmaceutical Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a pharmaceutical company specializing in innovative drug formulations. The company develops ready-to-use injectable treatments for conditions like diabetes and rare... Read More

  • 3 E-Commerce Stocks To Buy Now

    Sea Limited (SE) Sea Limited is a digital services company with operations in e-commerce, gaming, and digital financial services. The company owns Shopee, Garena, and SeaMoney, offering internet-based consumer and... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    Cumberland Pharmaceuticals Inc. (CPIX) Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing hospital acute care and gastroenterology drugs. The company provides innovative treatments for underserved... Read More

  • 3 Semiconductor Stocks To Buy Now

    Allegro MicroSystems, Inc. (ALGM) Allegro MicroSystems, Inc. is a semiconductor company specializing in power and sensing solutions. The company develops high-performance integrated circuits for automotive, industrial, and consumer applications, enhancing... Read More

  • 3 Pharma Stocks To Buy Now

    Arcutis Biotherapeutics, Inc. (ARQT) Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative dermatology treatments. The company specializes in topical therapies for inflammatory skin conditions such as psoriasis... Read More

  • 3 Finance Stocks To Buy Now

    Hanover Insurance Group Inc. (THG) Hanover Insurance Group Inc. is a property and casualty insurance company providing coverage for businesses, individuals, and specialty markets. The company offers a range of... Read More

  • 3 Tech Service Stocks To Buy Now

    Sezzle Inc. (SEZL) Sezzle Inc. is a financial technology company that provides buy now, pay later (BNPL) solutions. The platform allows consumers to split purchases into interest-free installments, supporting merchants... Read More